Chelsea McLean

1.8k total citations
21 papers, 552 citations indexed

About

Chelsea McLean is a scholar working on Infectious Diseases, Molecular Biology and Oncology. According to data from OpenAlex, Chelsea McLean has authored 21 papers receiving a total of 552 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Chelsea McLean's work include Viral Infections and Outbreaks Research (8 papers), Epigenetics and DNA Methylation (6 papers) and Hepatitis B Virus Studies (4 papers). Chelsea McLean is often cited by papers focused on Viral Infections and Outbreaks Research (8 papers), Epigenetics and DNA Methylation (6 papers) and Hepatitis B Virus Studies (4 papers). Chelsea McLean collaborates with scholars based in Netherlands, Belgium and United States. Chelsea McLean's co-authors include Fred van Leeuwen, Ino D. Karemaker, Emile E. Voest, Kristian Helin, Gregoriy A. Dokshin, Diego Pasini, Salo Ooft, Mary E. Donohoe, Jeannie T. Lee and Paul D. Soloway and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Chelsea McLean

19 papers receiving 546 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chelsea McLean Netherlands 10 345 140 103 58 57 21 552
Qiang Feng China 13 360 1.0× 170 1.2× 86 0.8× 106 1.8× 104 1.8× 51 571
Rene Quevedo Canada 9 249 0.7× 182 1.3× 110 1.1× 85 1.5× 44 0.8× 15 503
Anette Heller Germany 10 152 0.4× 188 1.3× 83 0.8× 52 0.9× 90 1.6× 13 365
Joana Carvalho United Kingdom 11 356 1.0× 207 1.5× 105 1.0× 121 2.1× 30 0.5× 13 552
John G. Logan United Kingdom 13 262 0.8× 126 0.9× 54 0.5× 49 0.8× 47 0.8× 19 513
Nina Frey Switzerland 7 207 0.6× 107 0.8× 51 0.5× 63 1.1× 40 0.7× 19 373
Luciane Sussuchi da Silva Brazil 11 192 0.6× 76 0.5× 88 0.9× 39 0.7× 38 0.7× 31 363
Juan Mo China 11 277 0.8× 97 0.7× 113 1.1× 46 0.8× 91 1.6× 33 483

Countries citing papers authored by Chelsea McLean

Since Specialization
Citations

This map shows the geographic impact of Chelsea McLean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chelsea McLean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chelsea McLean more than expected).

Fields of papers citing papers by Chelsea McLean

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chelsea McLean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chelsea McLean. The network helps show where Chelsea McLean may publish in the future.

Co-authorship network of co-authors of Chelsea McLean

This figure shows the co-authorship network connecting the top 25 collaborators of Chelsea McLean. A scholar is included among the top collaborators of Chelsea McLean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chelsea McLean. Chelsea McLean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nyombayire, Julien, Susan Allen, Amanda Tichacek, et al.. (2025). Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial. Nature Medicine. 31(11). 3899–3906.
2.
3.
Goldstein, Neil, Chelsea McLean, Auguste Gaddah, et al.. (2024). Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial. Human Vaccines & Immunotherapeutics. 20(1). 2327747–2327747. 4 indexed citations
4.
Robinson, Cynthia, Michael Katwere, Chelsea McLean, et al.. (2023). Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo. The Journal of Infectious Diseases. 229(4). 1068–1076. 2 indexed citations
5.
Prague, Mélanie, Chelsea McLean, Viki Bockstal, et al.. (2023). Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. npj Vaccines. 8(1). 174–174.
6.
Blengio, Fabiola, Hakim Hocini, Laura Richert, et al.. (2023). Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo. Cell Reports. 42(9). 113101–113101. 7 indexed citations
7.
McLean, Chelsea, Karin Dijkman, Auguste Gaddah, et al.. (2023). Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans. Frontiers in Immunology. 14. 1215302–1215302. 6 indexed citations
8.
9.
Ooft, Salo, Fleur Weeber, Luuk J. Schipper, et al.. (2021). Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open. 6(3). 100103–100103. 89 indexed citations
10.
Aslam, Muhammad Assad, Mir Farshid Alemdehy, Teun van den Brand, et al.. (2020). The histone methyltransferase DOT1L prevents antigen-independent differentiation and safeguards epigenetic identity of CD8 + T cells. Proceedings of the National Academy of Sciences. 117(34). 20706–20716. 32 indexed citations
11.
Nadal, Ernest, Evert Bosdriesz, Salo Ooft, et al.. (2020). Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nature Communications. 11(1). 3157–3157. 67 indexed citations
12.
Vlaming, Hanneke, Chelsea McLean, Mir Farshid Alemdehy, et al.. (2019). Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L‐dose dependency in HDAC1‐deficient thymic lymphoma. The EMBO Journal. 38(14). e101564–e101564. 33 indexed citations
13.
Lavitrano, Marialuisa, Leonarda Ianzano, Sara Bonomo, et al.. (2019). BTK inhibitors synergise with 5‐FU to treat drug‐resistant TP53‐null colon cancers. The Journal of Pathology. 250(2). 134–147. 28 indexed citations
14.
McLean, Chelsea, et al.. (2016). Imprinted DNA methylation reconstituted at a non-imprinted locus. Epigenetics & Chromatin. 9(1). 41–41. 2 indexed citations
15.
Houthuijzen, Julia M., Brian D. Hudson, Akira Hirasawa, et al.. (2016). Abstract 307: GPR120/FFAR4 activation by fatty acid 16:4(n-3) plays a key role in resistance to chemotherapy. Cancer Research. 76(14_Supplement). 307–307. 2 indexed citations
16.
Zimberlin, Cheryl, Cesare Lancini, Sanne L. Rosekrans, et al.. (2015). HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis. The FASEB Journal. 29(5). 2070–2080. 36 indexed citations
17.
McLean, Chelsea, Ino D. Karemaker, & Fred van Leeuwen. (2014). The emerging roles of DOT1L in leukemia and normal development. Leukemia. 28(11). 2131–2138. 94 indexed citations
18.
Wolfe, Rory, et al.. (2013). The Role of Mitotic Rate in Melanoma Survival in a Cohort of 1396 Australian Patients. Australasian Journal of Dermatology. 11. 1 indexed citations
19.
Godfrey, Keith M., Peter D. Gluckman, Karen A. Lillycrop, et al.. (2009). 6th World Congress on Developmental Origins of Health and Disease. Journal of Developmental Origins of Health and Disease. 1(S1). S1–S60. 6 indexed citations
20.
Lindroth, Anders M., Yoon Jung Park, Chelsea McLean, et al.. (2008). Antagonism between DNA and H3K27 Methylation at the Imprinted Rasgrf1 Locus. PLoS Genetics. 4(8). e1000145–e1000145. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiang Feng Breakdown of academic impact, for papers by Rene Quevedo Breakdown of academic impact, for papers by Anette Heller Breakdown of academic impact, for papers by Joana Carvalho Breakdown of academic impact, for papers by John G. Logan Breakdown of academic impact, for papers by Nina Frey Breakdown of academic impact, for papers by Luciane Sussuchi da Silva Breakdown of academic impact, for papers by Juan Mo
Rankless by CCL
2026